The UK and US have reached a key bilateral deal that will preserve zero import taxes on UK pharmaceutical products going into the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to boost expenditure on medicines through the NHS. This pledge guarantees that duties on these key exports will be held at zero for a timeframe of three years.
This development is in response to recent statements to significantly raise duties on patented pharmaceutical imports, with potential rates discussed as high as one hundred percent.
"This arrangement with the Britain reinforces the worldwide climate for cutting-edge drugs and introduces much-needed equity to American-British medicine commerce," an announcement said.
Commercial Impact
Medicines are one of the the United Kingdom's most significant exports to the America, which is easily the biggest destination for leading UK drugmakers.
Export figures reveal that in the 12 months leading up to the third quarter, the UK exported pharmaceutical products valued at £11.1bn to the US. This figure accounted for nearly one-fifth of total UK exports in that span.
"This guarantee safeguards work, boosts funding and sets the stage for the UK to become a international leader for medical research," a minister stated.
Specific UK Commitments
The deal entails several notable commitments from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new medicines to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to raise total public funding on medicines from 0.3% of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to control costs will be limited at fifteen percent. Previously, rebates were more than 20%.
Industry Background
This agreement comes amid a long-running tension between the drug companies and the British authorities over spending levels and approval rates.
This friction were intensified by arguments that American consumers were paying significantly more for the equivalent treatments than people in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been paused or scrapped, while major expansions have been directed toward US facilities.
A senior figure stated that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the past decade.
